Loading market movers...

BAY2599023 (DTX201)

Phase 2

Phase 2

Development Phase

0

Upcoming Catalysts

1

Historical Events

0

Regulatory Approvals

Development History

Sep '26

BAYRYPhase 2$55.5B

✓Completed

BAY2599023 (DTX201) Phase 2 Est. Readout

BAY2599023 (DTX201)• Hemophilia A11

Sep 2026~Confirmed

Competitive Landscape

3 competitors in Hemophilia A

SNYefanesoctocog alfa (BIVV001)

View Full Landscape

Drug Information

Target Indication

Hemophilia A

Clinical Trial

Last updated: 1/13/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

BAYRY

BAYER

Healthcare•Europe•NASDAQ

Related Pipeline

Cipro XR (Ciprofloxacin, BAYQ3939)Phase 3

Urinary Tract Infection

DabigatranPhase 3

Hematoma

bemdaneprocelPhase 3

Parkinsons Disease (PD)

D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IVPhase 3

Acute Coronary Syndrome

Finerenone (Kerendia, BAY94-8862)Phase 3

Chronic Kidney Disease

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts